Sarpogrelate

Sarpogrelate is a drug that is classified as a serotonin 2A receptor antagonist. It is primarily used in the treatment of peripheral arterial disease (PAD) and claudication. Sarpogrelate is marketed in Japan and South Korea by Mitsubishi Tanabe Pharma Corporation under the brand name Anplag.

Mechanism of Action

Sarpogrelate works by inhibiting the action of serotonin on its 2A receptor. This results in a decrease in platelet aggregation, which can help to prevent the formation of blood clots. It also has a vasodilatory effect, which can help to improve blood flow in patients with peripheral arterial disease.

Uses

Sarpogrelate is used in the treatment of peripheral arterial disease and claudication. It can help to improve symptoms such as pain and cramping in the legs that are caused by reduced blood flow.

Side Effects

Common side effects of sarpogrelate include nausea, vomiting, diarrhea, and abdominal pain. In rare cases, it can cause serious side effects such as bleeding, thrombocytopenia, and leukopenia.

Contraindications

Sarpogrelate is contraindicated in patients with a history of hypersensitivity to the drug or any of its components. It is also contraindicated in patients with severe liver disease or kidney disease.

See Also

• Peripheral artery disease
• Serotonin receptor antagonist
• Platelet aggregation

Sarpogrelate Resources
Latest articles Most recent articles Ongoing trials	Wikipedia

References

External Links

• Mitsubishi Tanabe Pharma Corporation